Recently, Habbout et al. found that EZH2 is overexpressed in PASMCs from patients with PAH and that EZH2 inhibition with GSK126, an EZH2-specific inhibitor, reduces PASMC proliferation in vitro [68]. The gene discussed is EZH2; the disease is pulmonary arterial hypertension.